Research Analysts Issue Forecasts for WVE FY2026 Earnings

Wave Life Sciences Ltd. (NASDAQ:WVE) – Stock analysts at B. Riley dropped their FY2026 earnings estimates for Wave Life Sciences in a research note issued on Thursday, April 10th. B. Riley analyst M. El-Saadi now expects that the company will post earnings per share of ($1.15) for the year, down from their prior forecast of ($0.96). The consensus estimate for Wave Life Sciences’ current full-year earnings is ($1.14) per share. B. Riley also issued estimates for Wave Life Sciences’ FY2027 earnings at ($0.25) EPS, FY2028 earnings at $0.14 EPS and FY2029 earnings at $0.84 EPS.

Several other research firms have also recently weighed in on WVE. Wedbush assumed coverage on Wave Life Sciences in a research report on Tuesday, April 8th. They set an “outperform” rating and a $18.00 price objective for the company. Jefferies Financial Group initiated coverage on shares of Wave Life Sciences in a research note on Tuesday, February 25th. They set a “buy” rating and a $26.00 price target for the company. StockNews.com raised shares of Wave Life Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, March 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $22.00 target price on shares of Wave Life Sciences in a research report on Wednesday, March 26th. Two equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Wave Life Sciences currently has an average rating of “Moderate Buy” and an average price target of $22.18.

Wave Life Sciences Stock Up 6.2 %

Shares of NASDAQ:WVE opened at $6.00 on Monday. The firm has a market cap of $920.92 million, a price-to-earnings ratio of -5.41 and a beta of -0.93. Wave Life Sciences has a 12 month low of $4.25 and a 12 month high of $16.74. The company’s fifty day simple moving average is $9.32 and its 200 day simple moving average is $11.66.

Wave Life Sciences (NASDAQ:WVE) last released its quarterly earnings data on Tuesday, March 4th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.34. The business had revenue of $83.75 million for the quarter, compared to analysts’ expectations of $25.60 million. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%.

Insiders Place Their Bets

In other news, Director Christian O. Henry sold 10,500 shares of the stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $9.77, for a total value of $102,585.00. Following the completion of the transaction, the director now owns 16,115 shares of the company’s stock, valued at approximately $157,443.55. This represents a 39.45 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Paul Bolno sold 169,025 shares of Wave Life Sciences stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $9.57, for a total transaction of $1,617,569.25. Following the sale, the chief executive officer now directly owns 338,351 shares in the company, valued at $3,238,019.07. This trade represents a 33.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 29.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. GF Fund Management CO. LTD. acquired a new position in Wave Life Sciences in the 4th quarter worth about $40,000. Quarry LP bought a new stake in shares of Wave Life Sciences during the fourth quarter worth about $62,000. KBC Group NV acquired a new position in shares of Wave Life Sciences in the fourth quarter valued at approximately $67,000. Summit Investment Advisors Inc. raised its holdings in Wave Life Sciences by 31.5% in the 4th quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company’s stock valued at $119,000 after buying an additional 2,308 shares during the last quarter. Finally, Orion Portfolio Solutions LLC acquired a new stake in Wave Life Sciences during the 3rd quarter worth approximately $123,000. 89.73% of the stock is currently owned by institutional investors.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.